This study is designed as a double-blind randomized, placebo-controlled, study investigating the safety, tolerability, and efficacy of XPro1595 in patients with mild AD with inflammation (ADi). The planned dose is 1.0 mg/kg of XPro1595 and matching placebo.
The purpose of this study is to measure cognitive and biological biomarkers in subcutaneously administered XPro1595 or placebo in patients with mild ADi.